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AbstrACt
Objective Idiopathic intracranial hypertension (IIH) is 
under-researched and the aim was to determine the top 
10 research priorities for this disease.
Design A modified nominal group technique was used to 
engage participants who had experience of IIH.
setting This James Lind Alliance Priority Setting 
Partnership was commissioned by IIH UK, a charity.
Participants People with IIH, carers, family and friends, 
and healthcare professionals participated in two rounds of 
surveys to identify unique research questions unanswered 
by current evidence. The most popular 26 uncertainties 
were presented to stakeholders who then agreed the top 
10 topics.
results The top 10 research priorities for IIH included 
aetiology of IIH, the pathological mechanisms of headache 
in IIH, new treatments in IIH, the difference between acute 
and gradual visual loss, the best ways to monitor visual 
function, biomarkers of the disease, hormonal causes of 
IIH, drug therapies for the treatment of headache, weight 
loss and its role in IIH and finally, the best intervention to 
treat IIH and when should surgery be performed.
Conclusions This priority setting encouraged people 
with direct experience of IIH to collectively identify 
critical gaps in the existing evidence. The overarching 
research aspiration was to understand the aetiology and 
management of IIH.
IntrODuCtIOn  
Clinical uncertainty in idiopathic intracranial 
hypertension (IIH) is evident, with the first 
consensus guidelines for investigation and 
management stating uncertainties in every 
aspect of the disease.1 The 2015 Cochrane 
review concluded that there is a lack of 
evidence to guide pharmacological treat-
ment.2 There are a few published randomised 
clinical trials3 4 and a small number of 
ongoing trials.5 6 Research is infrequent due 
to the rarity of the IIH7 8 and the lack of 
understanding of the underlying pathology.9 
IIH predominantly affects overweight 
women of childbearing age with the incidence 
of the disease documented to be rising10 with 
the increasing prevalence of obesity.7 8 In 
those with severely affected vision, surgery 
may be indicated.1 For the majority, it can 
be a chronic condition, with headaches 
impacting on the quality of life of patients,11 
and an economic burden.10 12
Understanding where research should 
be directed was a priority for IIH UK, the 
leading charity for IIH in the UK. The James 
Lind Alliance (JLA), a UK National Institute 
for Health Research-supported initiative, 
aims to provide a transparent process that 
enables patients and healthcare professionals 
(HCP) to work together to agree on the 
most important uncertainties to inform the 
research agenda. The aim of this IIH Priority 
Setting Partnership (PSP) was to identify gaps 
in knowledge that matter most to key stake-
holders (patients, carers and clinicians), and 
to indicate where future funding should be 
placed.
strengths and limitations of this study
 ► This is the first collaboration of patients, carers and 
clinicians with experience of idiopathic intracranial 
hypertension (IIH) to achieve consensus on the pri-
orities for future research.
 ► The James Lind Alliance (JLA) methods are patient 
centred and give funding bodies an unbiased agen-
da for research in IIH.
 ► Using online surveys as the main method for gath-
ering questions for this Priority Setting Partnership 
(PSP) may mean that not all those with experience of 
IIH were aware or able to participate in the process.
 ► It is conceivable that possibly all the research ques-
tions gathered are not exhaustive.
 ► While the JLA process and IIH PSP study recom-
mend those research priorities that are important, 
there is no guarantee of research funding.
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MethODs
IIh PsP process
The University of Birmingham, UK, acted as an academic 
partner to the IIH PSP and the process was led by the 
IIH UK research representative, in collaboration with the 
JLA ( www. jla. nihr. ac. uk). A steering group with represen-
tation from IIH UK, patients and all the major speciali-
ties associated with IIH plus an independent information 
specialist oversaw the process (online supplementary 
table 1). In February 2017, key organisations accepted 
the invitation to become partners. They included Asso-
ciation of British Neurologists, British Association for the 
Study of Headache, British and Irish Orthoptic Society, 
Fight for Sight, The Royal College of Ophthalmologists, 
Society of British Neurological Surgeons cerebrospinal 
fluid (CSF) group, Shine, Neurological Alliance and The 
United Kingdom Neuro-Ophthalmology Special Interest 
Group (online supplementary table 2). The PSP stages 
were broadly based on the four-step process developed by 
the JLA (figure 1).13
This PSP was concerned with adult IIH only and any 
responses exclusively relating to children were excluded. 
There was limited funding for the project, and including 
the paediatric population would have required funding 
for two different work streams. It is well documented the 
expectantly different phenotype between adult and those 
prepubescent children with IIH.14 However, responses 
were not limited by those who submitted and hence, those 
with children with IIH are likely to be included. Indeed, 
at the final stakeholder meeting, there was representation 
from carers of children with IIH. Responses concerning 
the classification of the disease, healthcare funding/enti-
tlements or statements without a discernible question 
were excluded.
The prioritisation survey questions were constructed 
(online supplementary table 2) by the steering group, 
aided by the first guidelines in IIH where uncertainties 
exist around the diagnosis, investigation and manage-
ment.1 This first survey was advertised by partners 
(online supplementary table 3), IIH UK and steering 
Figure 1 Consort diagram and details of the JLA IIH PSP. IIH, idiopathic intracranial hypertension; JLA, James Lind Alliance; 
PSP, Priority Setting Partnership.
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group members. All responses were refined to under-
standable ‘uncertainties’ with the exception of those 
considered to be ‘out of scope’. These were categorised 
using the UK Clinical Research Collaboration Health 
Research Classification System, sorted into themes and 
then formulated into indicative questions by steering 
group members, working in groups with at least one 
HCP and one patient representative. A literature search 
was conducted with the electronic databases, CENTRAL, 
Embase and MEDLINE, searched from inception to 
March 2018 for systematic reviews using strategies based 
on those used by Piper et al.2 The ‘known knowns’ with 
reference to the appropriate literature and duplicate 
questions were removed. Questions were amalgamated 
when practical to do so. The long list was then verified 
by the PSP lead and discussions were held with the wider 
steering group if disagreements occurred.
The known unknowns were then used for the interim 
survey. Respondents ranked the questions, returning 
their top 10. The rankings were reverse scored and the 
total scores for the two groups, individuals with IIH, 
friends or carers, and HCP, were calculated separately to 
ensure an equal weighting. The most popular 26 ques-
tions were then taken forward, which included the top 
10 for both groups, to the final workshop, with the aim of 
consensus on the top 10 priorities.13 Data relating to the 
PSP are available on reasonable request to IIH UK ( www. 
iih. org. uk).
Patient and public involvement
This research priority partnership was established by IIH 
UK, a charity that is run by carers and people with IIH. 
At each stage of the JLA process, patients and carers were 
equal collaborators in the design and decisions including 
the survey design and piloting, survey participation and 
the final workshop. They disseminated the surveys on 
the charity website and via social media. All participants 
were able to indicate a desire for further involvement and 
information about the results.
results
The prioritisation survey generated 356 responses 
(figure 1). Demographic data for those with IIH is 
provided in online supplementary table 4 and details of 
HCP specialisms in online supplementary table 5. Of the 
2405 generated uncertainties, 140 were out of scope. The 
resulting 2265 were grouped into 64 indicative questions. 
Sixteen were deemed to be already known or unanswer-
able by research, leaving 48 questions for presentation 
in the interim survey. Responses from 512 people were 
collected in a ratio of 4:1 people with IIH, friends and 
carers to HCP.
A final list of 26 prioritised questions was generated from 
the analysis of the interim survey, which included the top 
10 for both groups (online supplementary table 6). The 
most common themes from non-HPC (healthcare profes-
sional) were why the disease develops and progresses, 
hormonal causes and female predominance and the 
conditions associated with IIH. For HCP education, the 
utility of biomarkers and biological mechanisms of head-
ache were the most common. At the consensus workshop, 
the top 10 priorities were agreed (figure 2; online supple-
mentary table 7).
DIsCussIOn
Understanding the most relevant research projects to 
fund can be challenging. It is imperative that the topics 
identified in a disease area have the utmost relevance to 
patients affected by the disease and recognised by clini-
cians that have a clear understanding of the clinical 
entity. We have undertaken a JLA PSP to establish the top 
10 research areas for IIH.
The IIH JLA PSP was funded by IIH UK and set up 
those who have an active collaboration to improve care 
for people with IIH.15 The principles and structured 
process outlined by the JLA was adhered to steadfastly 
throughout.13 All data was maintained in a manner that 
could be tracked back at any point to the original questions 
and demographic source; this provided transparency.
A major challenge for the IIH PSP steering group was 
to engage all the relevant HCP (namely, neurologists, 
Figure 2 Final top 10 ranked uncertainties for concerning 
the treatment and management of people with idiopathic 
intracranial hypertension (IIH).
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ophthalmologists, neurosurgeons, radiologists and 
orthoptists). The speciality diversity brought strength to 
the process and allowed for a broad inclusion; however, 
during the final selection for the top 10, clinicians were 
clearly polarised by their individual specialism. There are 
a number of surgical treatments for fulminant visual loss 
in the form of CSF diversion, as directed by neurosur-
geons, and optic nerve sheath fenestration, as performed 
by ophthalmic surgeons.16 More recently, interventional 
radiologists have performed venous sinus stenting for 
IIH.17 Physicians (both neurologists and ophthalmolo-
gists) use weight loss and medical therapies, such as acet-
azolamide and topiramate.1 18 This mix of specialism and 
approach in certain patient groups, that is those at threat 
of visual loss or with chronic headache, led to expectantly 
different opinions; for example, surgeons were keen for 
novel interventions, whereas physicians were promoting 
better medical therapies.
At the interim survey, it was clear that there was a 
discrepancy between the non-HCP and HCP in their most 
popular themes, with patients keen for research into the 
aetiology, and HCP more commonly ranked education, 
biomarkers and pathological mechanisms driving head-
ache. The top priority of the patients’ group at the interim 
survey was the same as the final result of the consensus 
workshop.
Some differing opinions between non-HCP and 
HCP were expressed at the workshop. One issue was 
surrounding weight loss, seen by physicians as the only 
disease modifiable therapy and so a high priority for 
further understanding. This was a highly sensitive issue 
among the patients and carers present who voiced that 
it was not considered so important by patients. During 
the workshop, a collective decision was made to have a 
wide scope within the top 10 areas. If a topic was already 
featured high within the list, questions that contained a 
similar theme were purposely voted lower. For example, 
weight loss, the longer more detailed question was ranked 
higher than the question regarding bariatric surgery, with 
the reasoning that it could be answered not only by the 
weight loss question but also by number 10, the interven-
tion question. For this reason, no further ranking below 
the top 10 should be published. Of note, two areas that 
did not feature in the top 10, namely, multidisciplinary 
clinics and an education programme. They were scored 
as important during the interim survey, particularly by 
HPC. The consensus workshop delegates agreed that 
although these are highly important, the PSP is intended 
to inform grant bodies who fund research and these areas 
were universally accepted to require improvement.
strengths
Within the feedback, people with IIH voiced that they felt 
their opinions were often not heard; therefore, the IIH 
PSP has allowed them a voice. There was a good response 
rate from all groups when considering how rare IIH is. 
Submissions with low duplication rates were not removed, 
a process which can introduce bias. All submitted 
uncertainties were considered in the long list if they were 
determined to be known unknowns, including those 
asked by a single respondent. The data analysis followed 
standard protocols, though it was complicated by the use 
of multiple questions in the initial survey (online supple-
mentary table 3) as each respondent could appear in up 
to seven separate initial categories.
limitations
Despite the use of identification codes, the multi-level 
process meant that the number of individuals contrib-
uting to the final data set could not be reasonably calcu-
lated. The project took 18 months and surveys were closed 
on schedule, leaving the possibility that this happened 
before the maximum number of respondents could 
contribute. Using online surveys as the main method for 
gathering questions for this PSP may mean that not all 
those with experience of IIH were aware or able to partic-
ipate in the process. It is conceivable that possibly all the 
research questions gathered are not exhaustive. While 
the JLA process and IIH PSP study recommend those 
research priorities that are important, there is no guar-
antee of research funding.
COnClusIOns
The IIH PSP has been an opportunity to understand 
the areas that are important to all. The primary topic of 
underlying aetiology requires work both clinically and 
within the basic laboratory research. Another key area 
highlighted by this PSP is that of mechanisms of head-
ache in IIH. There is increasing evidence regarding the 
phenotype of the IIH headache, which is a challenging 
tradition regarding the raised intracranial pressure 
(ICP) headache. 19 20 Future work should explore novel 
therapies for headache in IIH, which is the key driver in 
lowering the quality of life in this patient cohort.11 The 
PSP has the potential to influence the research agenda 
and consequently in time all area of management, from 
medical to surgical interventions for this currently idio-
pathic disease.
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